Information Provided By:
Fly News Breaks for April 27, 2015
TEVA, MYL
Apr 27, 2015 | 11:21 EDT
BMO Capital believes the "forceful" response by Mylan (MYL) when rejecting Teva's (TEVA) takeover proposal shows it is not going to sell to Teva without a fight. BMO thinks some investors may have thought Mylan would try to push Teva for a higher offer, but it feels this is not the case after Mylan called Teva's stock "low-quality" and bought up "significant global antitrust risk." BMO has a Market Perform rating on Mylan with an $82 price target.
News For MYL;TEVA From the Last 2 Days
There are no results for your query MYL;TEVA